Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Jihyung | - |
dc.contributor.author | Novick, Diego | - |
dc.contributor.author | Montgomery, William | - |
dc.contributor.author | Victoria Moneta, Maria | - |
dc.contributor.author | Duenas, Hector | - |
dc.contributor.author | Peng, Xiaomei | - |
dc.contributor.author | Maria Haro, Josep | - |
dc.date.available | 2020-02-28T15:41:39Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2015-10 | - |
dc.identifier.issn | 1177-889X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/11951 | - |
dc.description.abstract | Purpose: To assess the levels of quality of life (QoL) in major depressive disorder (MDD) patients treated with either duloxetine or a selective serotonin reuptake inhibitor (SSRI) as monotherapy for up to 6 months in a naturalistic clinical setting mostly in the Middle East, East Asia, and Mexico. Patients and methods: Data for this post hoc analysis were taken from a 6-month prospective observational study involving 1,549 MDD patients without sexual dysfunction. QoL was measured using the EQ-5D instrument. Depression severity was measured using the Clinical Global Impression of Severity and the 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16), while pain severity was measured using the pain items of the Somatic Symptom Inventory. Regression analyses were performed to compare the levels of QoL between duloxetine-treated (n=556) and SSRI-treated (n=776) patients, adjusting for baseline patient characteristics. Results: These MDD patients, on average, had moderately impaired QoL at baseline, and the level of QoL impairment was similar between the duloxetine and SSRI groups (EQ-5D score of 0.46 [SD=0.32] in the former and 0.47 [SD=0.33] in the latter, P=0.066). Both descriptive and regression analyses confirmed QoL improvements in both groups during follow-up, but duloxetine-treated patients achieved higher QoL. At 24 weeks, the estimated mean EQ-5D score was 0.90 in the duloxetine cohort, which was statistically significantly higher than that of 0.83 in the SSRI cohort (P<0.001). Notably, pain severity at baseline was also statistically significantly associated with poorer QoL during follow-up (P<0.001). In addition, this association was observed in the subgroup of SSRI-treated patients (P<0.001), but not in that of duloxetine-treated patients (P=0.479). Conclusion: Depressed patients treated with duloxetine achieved higher QoL, compared to those treated with SSRIs, possibly in part due to its moderating effect on the link between pain and poorer QoL. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | DOVE MEDICAL PRESS LTD | - |
dc.relation.isPartOf | PATIENT PREFERENCE AND ADHERENCE | - |
dc.title | Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000363170700001 | - |
dc.identifier.doi | 10.2147/PPA.S89870 | - |
dc.identifier.bibliographicCitation | PATIENT PREFERENCE AND ADHERENCE, v.9, pp.1481 - 1490 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-84944749648 | - |
dc.citation.endPage | 1490 | - |
dc.citation.startPage | 1481 | - |
dc.citation.title | PATIENT PREFERENCE AND ADHERENCE | - |
dc.citation.volume | 9 | - |
dc.contributor.affiliatedAuthor | Hong, Jihyung | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | depression | - |
dc.subject.keywordAuthor | antidepressant | - |
dc.subject.keywordAuthor | duloxetine | - |
dc.subject.keywordAuthor | SSRI | - |
dc.subject.keywordAuthor | quality of life | - |
dc.subject.keywordPlus | EMERGENT SEXUAL DYSFUNCTION | - |
dc.subject.keywordPlus | PAINFUL PHYSICAL SYMPTOMS | - |
dc.subject.keywordPlus | REMISSION RATES | - |
dc.subject.keywordPlus | DISORDER | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | ANTIDEPRESSANTS | - |
dc.subject.keywordPlus | PSYCHOTHERAPY | - |
dc.subject.keywordPlus | DISABILITY | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.